Separately, Zacks Investment Research raised shares of ELEKTA AB/ADR from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, October 23rd.
Shares of OTCMKTS EKTAY opened at $13.11 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $5.60 billion, a PE ratio of 39.71, a PEG ratio of 2.87 and a beta of 0.46. The stock’s 50 day moving average price is $13.32 and its 200-day moving average price is $13.16. ELEKTA AB/ADR has a twelve month low of $10.95 and a twelve month high of $14.76.
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Featured Article: Penny Stocks, What You Need To Know
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.